Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.
Antisense oligonucleotides complementary to specific mRNA sequences are widely used inhibitors of gene expression in vitro and in vivo . In vitro cationic lipids have been demonstrated to increase the pharmacological activity of antisense oligonucleotides by increasing cellular uptake and facilitating nuclear accumulation. We have investigated the intracellular fate of oligonucleotide/cationic lipid complexes using fluorescently labeled lipids and oligonucleotides targeted to protein kinase C-alpha. After addition to cells the lipids initially co-localized with the oligonucleotide on the cell surface and in fine punctate structures within the cytoplasm. At later times the oligonucleotide began to accumulate in the nucleus as well as the cytoplasm. In contrast, the cationic lipid remained localized to the cell surface and the cytoplasm and was never found in the nucleus. Expression of protein kinase C-alpha mRNA did not begin to decline until after oligonucleotide was seen in the nucleus. This was also coincident with the transient appearance of a smaller mRNA transcript believed to result from RNase H cleavage of protein kinase C-alpha mRNA. These data suggest that although cationic lipids facilitate uptake of oligonucleotides, the complex must disassociate before the oligonucleotide can gain access to the nucleus and induce degradation of targeted mRNA.
Marcusson
E G
EG
Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, CA 92008, USA.
Bhat
B
B
Manoharan
M
M
Bennett
C F
CF
Dean
N M
NM
D001896:Boron Compounds / Q000138:chemical synthesis* / Q000737:chemistry; D002467:Cell Nucleus / Q000378:metabolism; D004337:Drug Carriers; D005229:Fatty Acids, Monounsaturated / Q000737:chemistry / Q000493:pharmacokinetics; D005456:Fluorescent Dyes; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis* / Q000235:genetics; D007700:Kinetics; D008175:Lung Neoplasms; D015394:Molecular Structure; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D011493:Protein Kinase C / Q000096:biosynthesis* / Q000235:genetics; D051571:Protein Kinase C-alpha; D000644:Quaternary Ammonium Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics; D012333:RNA, Messenger / Q000096:biosynthesis; D013873:Thionucleotides; D014158:Transcription, Genetic / Q000187:drug effects*; D014407:Tumor Cells, Cultured
C112209:1-O-oleoyl-2-((BODIPY)-dodecanoyl)-N,N,N-trimethyl-3-aminopropane bromide; D001896:Boron Compounds; D004337:Drug Carriers; D005229:Fatty Acids, Monounsaturated; D005456:Fluorescent Dyes; D007527:Isoenzymes; D016376:Oligonucleotides, Antisense; D000644:Quaternary Ammonium Compounds; D012333:RNA, Messenger; D013873:Thionucleotides; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha; C070046:1,2-dioleoyloxy-3-(trimethylammonium)propane